9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 400

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Overall Survival (OS),  Progression-Free Survival (PFS),  Disease Control Rate (DCR), Duration of Disease Control

Interventions: NGR-hTNF plus Best Investigator’s Choice (BIC), Placebo plus Best Investigator’s Choice (BIC)

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Primary Purpose: Treatment

Primary Completion Date: December 2017

Completion Date: December 2017

Last  Posted Date: December 22, 2017

Location: Wilshire Oncology Medical Group, Corona, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT01098266

Was this article helpful?
Dislike 0